Previous close | 1.1000 |
Open | 1.1000 |
Bid | 0.6500 |
Ask | 1.7500 |
Strike | 320.00 |
Expiry date | 2024-06-21 |
Day's range | 1.1000 - 1.1000 |
Contract range | N/A |
Volume | |
Open interest | 181 |
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.